Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans

Journal of Hospital Medicine

Volumn 7, Issue 2, 2012, Pages 91-97

  Prabaker, Kavitha K ^a,b   Tran, Thuong P H ^a   Pratummas, Tamara ^a   Goetz, Matthew Bidwell ^a,c   Graber, Christopher J ^a,c  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Contrast; Nephrotoxicity; Reversible; Vancomycin

Indexed keywords

ADRENALIN; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; COTRIMOXAZOLE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; FUROSEMIDE; GENTAMICIN; HYPERTENSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; PHENYLEPHRINE; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BONE INFECTION; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN INFECTION; SOFT TISSUE INFECTION; VETERANS HEALTH;

ACUTE KIDNEY INJURY; COHORT STUDIES; FEMALE; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VANCOMYCIN; VETERANS;

EID: 84856669174     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.946     Document Type: Article

References (41)

1. Bancroft EA. Antimicrobial resistance: it's not just for hospitals. JAMA. 2007; 298: 1803-1804.
2. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007; 298: 1763-1771.
3. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother. 1998; 42: 1303-1304.
4. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997; 350: 1670-1673.
5. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997; 40: 135-136.
6. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003; 47: 3040-3045.
7. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007; 60: 788-794.
8. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004; 38: 448-451.
9. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006; 166: 2138-2144.
10. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004; 38: 1700-1705.
11. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42: 2398-2402.
12. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007; 44: 1208-1215.
13. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43: 925-942.
14. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009; 66: 82-98.
15. Dieterich C, Puey A, Lin S, et al. Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol Sci. 2009; 107: 258-269.
16. Oktem F, Arslan MK, Ozguner F, et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology. 2005; 215: 227-233.
17. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med. 1987; 83: 1091-1097.
18. Downs NJ, Neihart RE, Dolezal JM, Hodges GR. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med. 1989; 149: 1777-1781.
19. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother. 1983; 23: 138-141.
20. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother. 1993; 32: 325-334.
21. Mellor JA, Kingdom J, Cafferkey M, Keane CT. Vancomycin toxicity: a prospective study. J Antimicrob Chemother. 1985; 15: 773-780.
22. Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy. 1990; 10: 378-382.
23. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990; 25: 679-687.
24. Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother. 1985; 16: 235-241.
25. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008; 52: 1330-1336.
26. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009; 49: 507-514.
27. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007; 29: 1107-1115.
28. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010; 123: 1143-1149.
29. Lee-Such SC, Overholser BR, Munoz-Price LS. Nephrotoxicity associated with aggressive vancomycin therapy [abstract L-1298]. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Washington, DC: American Society for Microbiology.
30. Mora A, Dzintars D, Lat A, Frei CR, Echevarria K. Incidence of vancomycin nephrotoxicity in the absence of concomitant nephrotoxins or confounders [abstract A1-1294b]. In: Program and Abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Washington, DC: American Society for Microbiology.
31. Nguyen M, Wong J, Lee C, et al. Nephrotoxicity associated with high-dose versus standard-dose vancomycin therapy [abstract K-1096]. In: Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Washington, DC: American Society for Microbiology.
32. Rios E, Pounders CL, Allison T. Evaluation of vancomycin nephrotoxicity in patients with methicillin-resistant Staphylococcus aureus bacteremia [abstract A1-1294a]. In: Program and Abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Washington, DC: American Society for Microbiology.
33. Zimmerman AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy. 1995; 15: 85-91.
34. Teng CG, Rezai K, Itokazu GS, et al. Continuation of high dose vancomycin despite nephrotoxicity [abstract K-3486]. In: Abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting, Washington, DC, 2008. Washington, DC: American Society for Microbiology.
35. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med. 2010; 123: 182-187.
36. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 2011; 37: 95-101.
37. Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant. 2005; 20: 1542-1550.
38. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 2005; 68: 14-22.
39. Kshirsagar AV, Poole C, Mottl A, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol. 2004; 15: 761-769.
40. Ocak S, Gorur S, Hakverdi S, Celik S, Erdogan S. Protective effects of caffeic acid phenethyl ester, vitamin C, vitamin E and N-acetylcysteine on vancomycin-induced nephrotoxicity in rats. Basic Clin Pharmacol Toxicol. 2007; 100: 328-333.
41. Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009; 48: 713-721.